Boster Immunoleader

ELISA/assay

Human OPG PicoKine ELISA Kit

EK0480

1 x96 well plate

320 USD

Human OPG PicoKine ELISA Kit

EK0480

320 USD

Sandwich ELISA kit for Quantitative Detection of Human OPG

NSO, E22-L401

1 x96 well plate

93.7pg/ml-6000pg/ml

<5pg/ml

Sample 1: n=16; Mean(pg/ml): 843; Standard deviation: 40.5; CV(%): 4.8 Sample 2: n=16; Mean(pg/ml): 2186; Standard deviation: 111.5; CV(%): 5.1 Sample 3: n=16; Mean(pg/ml): 3627; Standard deviation: 214; CV(%): 5.9

Sample 1: n=24; Mean(pg/ml): 924; Standard deviation: 60.06; CV(%): 6.5 Sample 2: n=24; Mean(pg/ml): 2570; Standard deviation: 179.9; CV(%): 7 Sample 3: n=24; Mean(pg/ml): 4085; Standard deviation: 310.46; CV(%): 7.6

There is no detectable cross-reactivity with other relevant proteins.

Store at 4˚C for 6 months, at -20˚C for 12 months. Avoid multiple freeze-thaw cycles(Shipped with wet ice.)

This kit is used for quantitative detection of human OPG in cell culture supernates, serum, plasma(heparin, EDTA), saliva and urine.

Human

Catalog number Description Quantity - 96-well plate precoated with anti- human OPG antibody 1 ST0000-10 Lyophilized recombinant human OPG standard 10ng/tubex2 AR1107 Biotinylated anti- human OPG antibody 130ul(dilution 1:100) AR1103 Avidin-Biotin-Peroxidase Complex(ABC) 130ul(dilution 1:100) AR1106-1 Sample diluent buffer 30ml AR1106-2 Antibody diluent buffer 12ml AR1106-3 ABC diluent buffer 12ml AR1104 TMB color developing agent 10ml AR1105 TMB stop solution 10ml

Osteoprotegerin(OPG) is identical to osteoclastogenesis inhibitory factor(OCIF), a soluble member of the tumor-necrosis factor receptor family that inhibits osteoclastogenesis. OPG is considered to play an important role in the regulation of bone resorption by modifying osteoclast differentiation. Osteoprotegerin is an independent risk factor for the progression of atherosclerosis and onset of cardiovascular disease. It can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity. OPG system may play a critical role in the development of osteolytic bone disease in multiple myeloma and that targeting this system may have therapeutic potential. OPG also plays a role in the vascular system. The standard product used in this kit is recombinant OPG, a 55KDa glycoprotein.

TNFRSF11B

Tumor necrosis factor receptor superfamily member 11B

tumor necrosis factor receptor superfamily, member 11b

MGC29565 MGC93568 OCIF OPG Osteoclastogenesis inhibitory factor Osteoprotegerin TNFRSF 11B TNFRSF11B TR 1 TR1 TR11B_HUMAN Tumor necrosis factor receptor superfamily member 11B

O00300